Academic Journal
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.
| Τίτλος: | Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. |
|---|---|
| Συγγραφείς: | Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: toni_choueiri@dfci.harvard.edu., Eto M; Department of Urology, Kyushu University, Fukuoka, Japan., Motzer R; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., De Giorgi U; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola, Italy., Buchler T; Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic., Basappa NS; Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada., Méndez-Vidal MJ; Department of Medical Oncology, Hospital Universitario Reina Sofía, Maimonides Institute for Biomedical Research of Córdoba, Córdoba, Spain., Tjulandin S; Department of Clinical Pharmacology and Chemotherapy, N N Blokhin National Medical Research Center for Oncology, Ministry of Health of the Russian Federation, Moscow, Russia., Hoon Park S; Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Melichar B; Department of Oncology, Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic., Hutson T; Department of Medical Oncology, Texas Oncology-Baylor Charles A Sammons Cancer Center, Dallas, TX, USA., Alemany C; Department of Hematology and Oncology, AdventHealth Cancer Institute, Orlando, FL, USA., McGregor B; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Powles T; Department of Oncology, The Royal Free NHS Trust, London, England, UK; Department of Oncology, Barts Cancer Institute, Queen Mary Institute of London, London, UK., Grünwald V; Clinic for Urology and Clinic for Medical Oncology, University Hospital Essen, Essen, Germany., Alekseev B; Department of Onco-urology, P A Hertsen Moscow Cancer Research Institute, Moscow, Russia., Rha SY; Department of Medical Oncology, Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea., Kopyltsov E; State Institution of Healthcare 'Regional Clinical Oncology Dispensary', Omsk, Russia., Kapoor A; Division of Urology, Department of Surgery, Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada., Alonso Gordoa T; Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain., Goh JC; ICON Research, South Brisbane, QLD, Australia; Department of BioMedical Sciences, Queensland University of Technology, Brisbane, QLD, Australia., Staehler M; Department of Urology, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany., Merchan JR; Department of Medicine, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA., Xie R; Biostatistics, Eisai, Nutley, NJ, USA., Perini RF; Clinical Research, Merck, Rahway, NJ, USA., Mody K; Clinical Research, Eisai, Nutley, NJ, USA., McKenzie J; Clinical Research, Eisai, Nutley, NJ, USA., Porta CG; Interdisciplinary Department of Medicine, University of Bari 'A Moro', Bari, Italy. |
| Πηγή: | The Lancet. Oncology [Lancet Oncol] 2023 Mar; Vol. 24 (3), pp. 228-238. |
| Τύπος έκδοσης: | Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: London : Lancet Pub. Group, c2000- |
| Ιατρικοί όροι (MeSH): | Carcinoma, Renal Cell* , Kidney Neoplasms*, Female ; Humans ; Male ; Middle Aged ; Everolimus ; Follow-Up Studies ; Sunitinib ; Phenylurea Compounds ; Quinolines ; Antibodies, Monoclonal, Humanized |
| Περίληψη: | Background: In the primary analysis of the CLEAR study, lenvatinib plus pembrolizumab significantly improved progression-free survival and overall survival versus sunitinib in patients with advanced renal cell carcinoma (data cutoff Aug 28, 2020). We aimed to assess overall survival based on 7 months of additional follow-up. Methods: This is a protocol-prespecified updated overall survival analysis (data cutoff March 31, 2021) of the open-label, phase 3, randomised CLEAR trial. Patients with clear-cell advanced renal cell carcinoma who had not received any systemic anticancer therapy for renal cell carcinoma, including anti-vascular endothelial growth factor therapy, or any systemic investigational anticancer drug, were eligible for inclusion from 200 sites (hospitals and cancer centres) across 20 countries. Patients were randomly assigned (1:1:1) to receive lenvatinib (20 mg per day orally in 21-day cycles) plus pembrolizumab (200 mg intravenously every 21 days; lenvatinib plus pembrolizumab group), lenvatinib (18 mg per day orally) plus everolimus (5 mg per day orally; lenvatinib plus everolimus group [not reported in this updated analysis]) in 21-day cycles, or sunitinib (50 mg per day orally, 4 weeks on and 2 weeks off; sunitinib group). Eligible patients were at least 18 years old with a Karnofsky performance status of 70 or higher. A computer-generated randomisation scheme was used, and stratification factors were geographical region and Memorial Sloan Kettering Cancer Center prognostic groups. The primary endpoint was progression-free survival assessed by independent imaging review according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). In this Article, extended follow-up analyses for progression-free survival and protocol-specified updated overall survival data are reported for the intention-to-treat population. No safety analyses were done at this follow-up. This study is closed to new participants and is registered with ClinicalTrials.gov, NCT02811861. Findings: Between Oct 13, 2016, and July 24, 2019, 1417 patients were screened for inclusion in the CLEAR trial, of whom 1069 (75%; 273 [26%] female, 796 [74%] male; median age 62 years [IQR 55-69]) were randomly assigned: 355 (33%) patients (255 [72%] male and 100 [28%] female) to the lenvatinib plus pembrolizumab group, 357 (33%) patients (275 [77%] male and 82 [23%] female) to the sunitinib group, and 357 (33%) patients to the lenvatinib plus everolimus group (not reported in this updated analysis). Median follow-up for progression-free survival was 27·8 months (IQR 20·3-33·8) in the lenvatinib plus pembrolizumab group and 19·4 months (5·5-32·5) in the sunitinib group. Median progression-free survival was 23·3 months (95% CI 20·8-27·7) in the lenvatinib plus pembrolizumab group and 9·2 months (6·0-11·0) in the sunitinib group (stratified hazard ratio [HR] 0·42 [95% CI 0·34-0·52]). Median overall survival follow-up was 33·7 months (IQR 27·4-36·9) in the lenvatinib plus pembrolizumab group and 33·4 months (26·7-36·8) in the sunitinib group. Overall survival was improved with lenvatinib plus pembrolizumab (median not reached [95% CI 41·5-not estimable]) versus sunitinib (median not reached [38·4-not estimable]; HR 0·72 [95% CI 0·55-0·93]). Interpretation: Efficacy benefits of lenvatinib plus pembrolizumab over sunitinib were durable and clinically meaningful with extended follow-up. These results support the use of lenvatinib plus pembrolizumab as a first-line therapy for patients with advanced renal cell carcinoma. Funding: Eisai and Merck Sharp & Dohme. (Copyright © 2023 Elsevier Ltd. All rights reserved.) |
| Competing Interests: | Declaration of interests TKC reports research funding, paid to their institution, from AstraZeneca, Aveo, Bayer, Bristol-Myers Squibb, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, Lilly, Merck, Nikang, Novartis, Pfizer, Roche, Sanofi/Aventis, and Takeda; consulting fees from AstraZeneca, Aravive, Aveo, Bayer, Bristol-Myers Squibb, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, IQVA, Infiniti, Ipsen, Kanaph, Lilly, Merck, Nikang, Novartis, Nuscan, Pfizer, Roche, Sanofi/Aventis, Surface Oncology, Takeda, Tempest, Up-To-Date, and CME events; payment or honoraria for lectures, presentations, manuscript writing, or educational events from AstraZeneca, Aravive, Aveo, Bayer, Bristol-Myers Squibb, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, IQVA, Infiniti, Ipsen, Kanaph, Lilly, Merck, Nikang, Novartis, Pfizer, Roche, Sanofi/Aventis, Takeda, Tempest, Up-To-Date, and CME events; support for attending meetings or travel from Eisai, Merck, Exelixis, and Pfizer; patents planned, issued, or pending related to ctDNA and biomarkers of response to immune checkpoint inhibitors (no royalties as of April 12, 2022); participated on a data safety monitoring board or advisory board for Aravive; a leadership or fiduciary role in other board, society, committee, or advocacy group, for KidneyCan (unpaid), committees for American Society of Clinical Oncology, European Society for Medical Oncology, National Comprehensive Cancer Network®, and Genitourinary Steering Committee of the National Cancer Institute; stock or stock options from Pionyr, Tempest, Precede Bio, and Osel; and salary and research support from Dana-Farber and Harvard Cancer Center Kidney SPORE (2P50CA101942-16) and Program 5P30CA006516-56, the Kohlberg Chair at Harvard Medical School, and the Trust Family, Michael Brigham, and Loker Pinard Funds for Kidney Cancer Research at Dana-Farber Cancer Institute. ME reports research funding from Kissei, Sanofi, Astellas, ONO, Takeda, and Bayer; and payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from MSD, ONO, Chugai, Novartis, Pfizer, Bristol Myers Squibb, Takeda, Janssen, and Merck. RM reports research funding, paid to their institution from Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Merck, Pfizer, and Aveo Pharmaceuticals and consulting fees from AstraZeneca, Aveo Pharmaceuticals, Eisai, EMD Serono, Exelixis, Genentech/Roche, Incyte, Lilly, Merck, Novartis, Pfizer, and Takeda. UDG reports payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Clovis oncology, Eisai, Janssen, MSD, Pfizer, Ipsen, and Roche and support for attending meetings or travel from Janssen, Bristol-Myers Squibb, and Ipsen. TB reports research support, paid to their institution from AstraZeneca, Roche, Bristol Myers Squibb, Exelixis, Merck, and Novartis; consulting fees from Bristol Myers Squibb, Astellas, Janssen, and Sanofi/Aventis; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Ipsen, Bristol-Myers Squibb, Servier, and Pfizer; and receipt of equipment, materials, drugs, medical writing, gifts, or other services, paid to their institution from Bristol-Myers Squibb, AstraZeneca, Roche, and Servier. NSB reports consulting fees from Bristol-Myers Squibb, Ipsen, Eisai, Janssen, Pfizer, Roche, Merck, EMD Serono, AstraZeneca, and Bayer; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events (personal) from Bristol-Myers Squibb, Ipsen, and Merck; and support for attending meetings or travel from Eisai and Janssen. MJM-V reports consulting fees from Astellas Pharma, Bristol-Myers Squibb, EUSA Pharma, Ipsen, Eisai, Janssen-Cilag, Novartis, Pfizer, Roche, and Sanofi; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Astellas Pharma, Bristol-Myers Squibb, Ipsen, EUSA Pharma, Janssen-Cilag, Pfizer, and Roche; and support for attending meetings or travel from Astellas Pharma, Bristol-Myers Squibb, Ipsen, Janssen-Cilag, Pfizer, and Roche. BM reports payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Roche, Pfizer, Bristol-Myers Squibb, Astellas, Novartis, Bayer, MSD, Merck Serono, Sanofi, Servier, AstraZeneca, Amgen, Janssen, Eisai, E Lilly, and Pierre Farbre; support for attending meetings or travel from Bristol-Myers Squibb and Merck Serono; and participation on a data safety monitoring board or advisory board for Roche, Pfizer, Bristol-Myers Squibb, Astellas, Novartis, Bayer, MSD, Merck Serono, Sanofi, Servier, AstraZeneca, Amgen, Janssen, Eisai, E Lilly, and Pierre Farbre. TH reports grants or contracts, paid to their institution, from Bristol-Myers Squibb, Eisai, Exelixis, Johnson & Johnson, and Pfizer; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Astellas Pharma, Bristol-Myers Squibb, Eisai, Exelixis, Johnson & Johnson, and Pfizer; and participation on a data safety monitoring board or advisory board for Astellas Pharma, Bayer/Onyx, Bristol Myers Squibb, Exelixis, Johnson & Johnson, Novartis, and Pfizer. BMcG reports grants or contracts, paid to their institution from Exelixis, SeaGen, Pfizer, Bristol Myers Squibb and consulting fees from Astellas, Bristol-Myers Squibb, Calithera, Eisai, Exelixis, Pfizer, and SeaGen. TP reports research funding from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; consulting fees from Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; support for attending meetings or travel Astra Zeneca, Ipsen, MSD, Pfizer, and Roche. VG reports grants or contracts, paid to their institution, from AstraZeneca, Bristol-Myers Squibb, MSD, Pfizer, Ipsen; consulting fees from Bristol-Myers Squibb, Pfizer, Roche, MSD, Oncorena, PCI Biotech, Nanobiotix, Merck Serono, EUSA Pharm, Debiopharm, Eisai, and Apogepha; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Bristol Myers Squibb, Eisai, Ipsen, Janssen-Cilag, Merck Serono, MSD, Novartis, Pfizer, Roche, AstraZeneca, and Astellas; support for attending meetings or travel from Pfizer and Merck; participation on a data safety monitoring board or advisory board for Bristol-Myers Squibb, Ipsen, Eisai, PharmaMar, and PharmaMar; leadership or fiduciary role in other board, society, committee, or advocacy group from National Working Group AIO (Working Group on Internal Oncology in the German Cancer Society), German Cancer Society; and stock or stock options in AstraZeneca, Bristol-Myers Squibb, MSD, and SeaGen. BA reports grants or contracts from Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Ipsen, Janssen, Merck, MSD, Pfizer, and Roche; consulting fees from Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Ipsen, Janssen, Merck, MSD, Pfizer, and Roche; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events: Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Ipsen, Janssen, Merck, MSD, Pfizer, Roche; payment for expert testimony from Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Ipsen, Janssen, Merck, MSD, Pfizer, and Roche; and support for attending meetings or travel from Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Ipsen, Janssen, Merck, MSD, Pfizer, and Roche. SYR reports grants or contracts from Amgen, Merck, Bristol-Myers Squibb, MSD, Lilly, Daiichi Sankyo, Beigene, Eisai, and AstraZeneca; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Amgen, Lilly, Bristol-Myers Squibb, MSD, and Eisai; and participation on a data safety monitoring board or advisory board from Amgen, MSD, Bristol-Myers Squibb, Merck, Indivumed, Beigene, Eisai, and Daiichi Sankyo. AK reports payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Merck, Bristol-Myers Squibb, Ipsen, Eisai, Janssen, AbbVie; leadership or fiduciary role in for Kidney Cancer Canada; and stock in Verity Pharma. TAG reports grants or contracts from Pfizer, Roche, and Ipsen; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Ipsen, Lilly, Pfizer, Roche, Bristol-Myers Squibb, MSD, Eisai, Bayer, Janssen, Sanofi, and Astellas. JCG reports consulting fees for an advisory board meeting from Merck Sharp & Dohme (Australia), Bristol-Myers Squibb, and GlaxoSmithKline; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Janssen–Cilag, Ipsen, Merck Sharp and Dohme (Australia), and AstraZeneca (Australia); and support for attending meetings or travel AstraZeneca (Australia), GlaxoSmithKline, and MSD. MS reports grants or contracts from Pfizer, GlaxoSmithKline, AVEO, Bristol Myers Squibb, Novartis, Bayer, Roche/Genentech, Immatics, Wilex, Ipsen, Exelixis, and Eisai; consulting fees from Pfizer, GlaxoSmithKline, Novartis, Bayer, Roche, Aveo, EUSA Pharm, Astellas, Ipsen, Exelixis, Pelloton, Eisai, Bristol-Myers Squibb, MSD, Apogepha, and Oncorena; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Pfizer, GlaxoSmithKline, AVEO, Novartis, Bayer, EUSA Pharma, Astellas, Ipsen, Exelixis, Pelloton, Eisai, Bristol-Myers Squibb, MSD, and Apogepha; and support for attending meetings or travel from Pfizer, EUSAPharm, Ipsen, Eisai, Bristol-Myers Squibb, MSD, and Apogepha. JRM reports grants or contracts, paid to their institution from Corvus Pharmaceuticals, Eisai, Genentech/Roche, Lilly, Merck, Novartis, Peloton Therapeutics, Pfizer, Replimune, Seattle Genetics/Astellas, Sillajen, Tizona Therapeutics, Tocagen, and Vyriad, and consulting fees from Exelixis. RX, KM, and JMcK are employees of Eisai. RFP is an employee of and holds stock in Merck, Rahway, NJ, USA. CGP reports consulting fees from Angelini Pharma, AstraZeneca, Bristol-Myers Squibb, Eisai, Ipsen, and MSD; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Angelini Pharma, AstraZeneca, Bristol-Myers Squibb, Eisai, General Electric, Ipsen, and MSD; and participation on a data safety monitoring board or advisory board for Bristol-Myers Squibb, Eisai, MSD, the European Society of Medical Oncology, and the Italian Association for Medical Oncology. All other authors declare no competing interests. |
| Σχόλια: | Erratum in: Lancet Oncol. 2023 Apr;24(4):e146. doi: 10.1016/S1470-2045(23)00117-1.. (PMID: 36990611) |
| Molecular Sequence: | ClinicalTrials.gov NCT02811861 |
| Substance Nomenclature: | 9HW64Q8G6G (Everolimus) V99T50803M (Sunitinib) EE083865G2 (lenvatinib) 0 (Phenylurea Compounds) 0 (Quinolines) DPT0O3T46P (pembrolizumab) 0 (Antibodies, Monoclonal, Humanized) |
| Entry Date(s): | Date Created: 20230301 Date Completed: 20230307 Latest Revision: 20260127 |
| Update Code: | 20260130 |
| DOI: | 10.1016/S1470-2045(23)00049-9 |
| PMID: | 36858721 |
| Βάση Δεδομένων: | MEDLINE |
| FullText | Links: – Type: other Url: https://resolver.ebsco.com:443/public/rma-ftfapi/ejs/direct?AccessToken=48E88FFBE5BE626B0506&Show=Object Text: Availability: 0 CustomLinks: – Url: https://www.doi.org/10.1016/S1470-2045(23)00049-9? Name: ScienceDirect (all content) (s7799221) Category: fullText Text: View record from ScienceDirect MouseOverText: View record from ScienceDirect |
|---|---|
| Header | DbId: cmedm DbLabel: MEDLINE An: 36858721 AccessLevel: 3 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Choueiri+TK%22">Choueiri TK</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: toni&#95;choueiri@dfci.harvard.edu.<br /><searchLink fieldCode="AU" term="%22Eto+M%22">Eto M</searchLink>; Department of Urology, Kyushu University, Fukuoka, Japan.<br /><searchLink fieldCode="AU" term="%22Motzer+R%22">Motzer R</searchLink>; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22De+Giorgi+U%22">De Giorgi U</searchLink>; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola, Italy.<br /><searchLink fieldCode="AU" term="%22Buchler+T%22">Buchler T</searchLink>; Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Basappa+NS%22">Basappa NS</searchLink>; Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.<br /><searchLink fieldCode="AU" term="%22Méndez-Vidal+MJ%22">Méndez-Vidal MJ</searchLink>; Department of Medical Oncology, Hospital Universitario Reina Sofía, Maimonides Institute for Biomedical Research of Córdoba, Córdoba, Spain.<br /><searchLink fieldCode="AU" term="%22Tjulandin+S%22">Tjulandin S</searchLink>; Department of Clinical Pharmacology and Chemotherapy, N N Blokhin National Medical Research Center for Oncology, Ministry of Health of the Russian Federation, Moscow, Russia.<br /><searchLink fieldCode="AU" term="%22Hoon+Park+S%22">Hoon Park S</searchLink>; Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Melichar+B%22">Melichar B</searchLink>; Department of Oncology, Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Hutson+T%22">Hutson T</searchLink>; Department of Medical Oncology, Texas Oncology-Baylor Charles A Sammons Cancer Center, Dallas, TX, USA.<br /><searchLink fieldCode="AU" term="%22Alemany+C%22">Alemany C</searchLink>; Department of Hematology and Oncology, AdventHealth Cancer Institute, Orlando, FL, USA.<br /><searchLink fieldCode="AU" term="%22McGregor+B%22">McGregor B</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Powles+T%22">Powles T</searchLink>; Department of Oncology, The Royal Free NHS Trust, London, England, UK; Department of Oncology, Barts Cancer Institute, Queen Mary Institute of London, London, UK.<br /><searchLink fieldCode="AU" term="%22Grünwald+V%22">Grünwald V</searchLink>; Clinic for Urology and Clinic for Medical Oncology, University Hospital Essen, Essen, Germany.<br /><searchLink fieldCode="AU" term="%22Alekseev+B%22">Alekseev B</searchLink>; Department of Onco-urology, P A Hertsen Moscow Cancer Research Institute, Moscow, Russia.<br /><searchLink fieldCode="AU" term="%22Rha+SY%22">Rha SY</searchLink>; Department of Medical Oncology, Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Kopyltsov+E%22">Kopyltsov E</searchLink>; State Institution of Healthcare 'Regional Clinical Oncology Dispensary', Omsk, Russia.<br /><searchLink fieldCode="AU" term="%22Kapoor+A%22">Kapoor A</searchLink>; Division of Urology, Department of Surgery, Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Alonso+Gordoa+T%22">Alonso Gordoa T</searchLink>; Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Goh+JC%22">Goh JC</searchLink>; ICON Research, South Brisbane, QLD, Australia; Department of BioMedical Sciences, Queensland University of Technology, Brisbane, QLD, Australia.<br /><searchLink fieldCode="AU" term="%22Staehler+M%22">Staehler M</searchLink>; Department of Urology, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Merchan+JR%22">Merchan JR</searchLink>; Department of Medicine, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA.<br /><searchLink fieldCode="AU" term="%22Xie+R%22">Xie R</searchLink>; Biostatistics, Eisai, Nutley, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Perini+RF%22">Perini RF</searchLink>; Clinical Research, Merck, Rahway, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Mody+K%22">Mody K</searchLink>; Clinical Research, Eisai, Nutley, NJ, USA.<br /><searchLink fieldCode="AU" term="%22McKenzie+J%22">McKenzie J</searchLink>; Clinical Research, Eisai, Nutley, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Porta+CG%22">Porta CG</searchLink>; Interdisciplinary Department of Medicine, University of Bari 'A Moro', Bari, Italy. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22100957246%22">The Lancet. Oncology</searchLink> [Lancet Oncol] 2023 Mar; Vol. 24 (3), pp. 228-238. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't – Name: Language Label: Language Group: Lang Data: English – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Lancet+Pub%2E+Group%22">Lancet Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100957246 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-5488 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214702045%22">14702045 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Oncol <i>Subsets: </i>MEDLINE – Name: PublisherInfo Label: Imprint Name(s) Group: PubInfo Data: <i>Original Publication</i>: London : Lancet Pub. Group, c2000- – Name: SubjectMESH Label: MeSH Terms Group: Su Data: <searchLink fieldCode="MM" term="%22Carcinoma%2C+Renal+Cell%22">Carcinoma, Renal Cell*</searchLink> <br /><searchLink fieldCode="MM" term="%22Kidney+Neoplasms%22">Kidney Neoplasms*</searchLink><br /><searchLink fieldCode="MH" term="%22Female%22">Female</searchLink> ; <searchLink fieldCode="MH" term="%22Humans%22">Humans</searchLink> ; <searchLink fieldCode="MH" term="%22Male%22">Male</searchLink> ; <searchLink fieldCode="MH" term="%22Middle+Aged%22">Middle Aged</searchLink> ; <searchLink fieldCode="MH" term="%22Everolimus%22">Everolimus</searchLink> ; <searchLink fieldCode="MH" term="%22Follow-Up+Studies%22">Follow-Up Studies</searchLink> ; <searchLink fieldCode="MH" term="%22Sunitinib%22">Sunitinib</searchLink> ; <searchLink fieldCode="MH" term="%22Phenylurea+Compounds%22">Phenylurea Compounds</searchLink> ; <searchLink fieldCode="MH" term="%22Quinolines%22">Quinolines</searchLink> ; <searchLink fieldCode="MH" term="%22Antibodies%2C+Monoclonal%2C+Humanized%22">Antibodies, Monoclonal, Humanized</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: Background: In the primary analysis of the CLEAR study, lenvatinib plus pembrolizumab significantly improved progression-free survival and overall survival versus sunitinib in patients with advanced renal cell carcinoma (data cutoff Aug 28, 2020). We aimed to assess overall survival based on 7 months of additional follow-up.<br />Methods: This is a protocol-prespecified updated overall survival analysis (data cutoff March 31, 2021) of the open-label, phase 3, randomised CLEAR trial. Patients with clear-cell advanced renal cell carcinoma who had not received any systemic anticancer therapy for renal cell carcinoma, including anti-vascular endothelial growth factor therapy, or any systemic investigational anticancer drug, were eligible for inclusion from 200 sites (hospitals and cancer centres) across 20 countries. Patients were randomly assigned (1:1:1) to receive lenvatinib (20 mg per day orally in 21-day cycles) plus pembrolizumab (200 mg intravenously every 21 days; lenvatinib plus pembrolizumab group), lenvatinib (18 mg per day orally) plus everolimus (5 mg per day orally; lenvatinib plus everolimus group [not reported in this updated analysis]) in 21-day cycles, or sunitinib (50 mg per day orally, 4 weeks on and 2 weeks off; sunitinib group). Eligible patients were at least 18 years old with a Karnofsky performance status of 70 or higher. A computer-generated randomisation scheme was used, and stratification factors were geographical region and Memorial Sloan Kettering Cancer Center prognostic groups. The primary endpoint was progression-free survival assessed by independent imaging review according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). In this Article, extended follow-up analyses for progression-free survival and protocol-specified updated overall survival data are reported for the intention-to-treat population. No safety analyses were done at this follow-up. This study is closed to new participants and is registered with ClinicalTrials.gov, NCT02811861.<br />Findings: Between Oct 13, 2016, and July 24, 2019, 1417 patients were screened for inclusion in the CLEAR trial, of whom 1069 (75%; 273 [26%] female, 796 [74%] male; median age 62 years [IQR 55-69]) were randomly assigned: 355 (33%) patients (255 [72%] male and 100 [28%] female) to the lenvatinib plus pembrolizumab group, 357 (33%) patients (275 [77%] male and 82 [23%] female) to the sunitinib group, and 357 (33%) patients to the lenvatinib plus everolimus group (not reported in this updated analysis). Median follow-up for progression-free survival was 27·8 months (IQR 20·3-33·8) in the lenvatinib plus pembrolizumab group and 19·4 months (5·5-32·5) in the sunitinib group. Median progression-free survival was 23·3 months (95% CI 20·8-27·7) in the lenvatinib plus pembrolizumab group and 9·2 months (6·0-11·0) in the sunitinib group (stratified hazard ratio [HR] 0·42 [95% CI 0·34-0·52]). Median overall survival follow-up was 33·7 months (IQR 27·4-36·9) in the lenvatinib plus pembrolizumab group and 33·4 months (26·7-36·8) in the sunitinib group. Overall survival was improved with lenvatinib plus pembrolizumab (median not reached [95% CI 41·5-not estimable]) versus sunitinib (median not reached [38·4-not estimable]; HR 0·72 [95% CI 0·55-0·93]).<br />Interpretation: Efficacy benefits of lenvatinib plus pembrolizumab over sunitinib were durable and clinically meaningful with extended follow-up. These results support the use of lenvatinib plus pembrolizumab as a first-line therapy for patients with advanced renal cell carcinoma.<br />Funding: Eisai and Merck Sharp & Dohme.<br /> (Copyright © 2023 Elsevier Ltd. All rights reserved.) – Name: Abstract Label: Competing Interests Group: Ab Data: Declaration of interests TKC reports research funding, paid to their institution, from AstraZeneca, Aveo, Bayer, Bristol-Myers Squibb, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, Lilly, Merck, Nikang, Novartis, Pfizer, Roche, Sanofi/Aventis, and Takeda; consulting fees from AstraZeneca, Aravive, Aveo, Bayer, Bristol-Myers Squibb, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, IQVA, Infiniti, Ipsen, Kanaph, Lilly, Merck, Nikang, Novartis, Nuscan, Pfizer, Roche, Sanofi/Aventis, Surface Oncology, Takeda, Tempest, Up-To-Date, and CME events; payment or honoraria for lectures, presentations, manuscript writing, or educational events from AstraZeneca, Aravive, Aveo, Bayer, Bristol-Myers Squibb, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, IQVA, Infiniti, Ipsen, Kanaph, Lilly, Merck, Nikang, Novartis, Pfizer, Roche, Sanofi/Aventis, Takeda, Tempest, Up-To-Date, and CME events; support for attending meetings or travel from Eisai, Merck, Exelixis, and Pfizer; patents planned, issued, or pending related to ctDNA and biomarkers of response to immune checkpoint inhibitors (no royalties as of April 12, 2022); participated on a data safety monitoring board or advisory board for Aravive; a leadership or fiduciary role in other board, society, committee, or advocacy group, for KidneyCan (unpaid), committees for American Society of Clinical Oncology, European Society for Medical Oncology, National Comprehensive Cancer Network®, and Genitourinary Steering Committee of the National Cancer Institute; stock or stock options from Pionyr, Tempest, Precede Bio, and Osel; and salary and research support from Dana-Farber and Harvard Cancer Center Kidney SPORE (2P50CA101942-16) and Program 5P30CA006516-56, the Kohlberg Chair at Harvard Medical School, and the Trust Family, Michael Brigham, and Loker Pinard Funds for Kidney Cancer Research at Dana-Farber Cancer Institute. ME reports research funding from Kissei, Sanofi, Astellas, ONO, Takeda, and Bayer; and payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from MSD, ONO, Chugai, Novartis, Pfizer, Bristol Myers Squibb, Takeda, Janssen, and Merck. RM reports research funding, paid to their institution from Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Merck, Pfizer, and Aveo Pharmaceuticals and consulting fees from AstraZeneca, Aveo Pharmaceuticals, Eisai, EMD Serono, Exelixis, Genentech/Roche, Incyte, Lilly, Merck, Novartis, Pfizer, and Takeda. UDG reports payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Clovis oncology, Eisai, Janssen, MSD, Pfizer, Ipsen, and Roche and support for attending meetings or travel from Janssen, Bristol-Myers Squibb, and Ipsen. TB reports research support, paid to their institution from AstraZeneca, Roche, Bristol Myers Squibb, Exelixis, Merck, and Novartis; consulting fees from Bristol Myers Squibb, Astellas, Janssen, and Sanofi/Aventis; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Ipsen, Bristol-Myers Squibb, Servier, and Pfizer; and receipt of equipment, materials, drugs, medical writing, gifts, or other services, paid to their institution from Bristol-Myers Squibb, AstraZeneca, Roche, and Servier. NSB reports consulting fees from Bristol-Myers Squibb, Ipsen, Eisai, Janssen, Pfizer, Roche, Merck, EMD Serono, AstraZeneca, and Bayer; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events (personal) from Bristol-Myers Squibb, Ipsen, and Merck; and support for attending meetings or travel from Eisai and Janssen. MJM-V reports consulting fees from Astellas Pharma, Bristol-Myers Squibb, EUSA Pharma, Ipsen, Eisai, Janssen-Cilag, Novartis, Pfizer, Roche, and Sanofi; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Astellas Pharma, Bristol-Myers Squibb, Ipsen, EUSA Pharma, Janssen-Cilag, Pfizer, and Roche; and support for attending meetings or travel from Astellas Pharma, Bristol-Myers Squibb, Ipsen, Janssen-Cilag, Pfizer, and Roche. BM reports payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Roche, Pfizer, Bristol-Myers Squibb, Astellas, Novartis, Bayer, MSD, Merck Serono, Sanofi, Servier, AstraZeneca, Amgen, Janssen, Eisai, E Lilly, and Pierre Farbre; support for attending meetings or travel from Bristol-Myers Squibb and Merck Serono; and participation on a data safety monitoring board or advisory board for Roche, Pfizer, Bristol-Myers Squibb, Astellas, Novartis, Bayer, MSD, Merck Serono, Sanofi, Servier, AstraZeneca, Amgen, Janssen, Eisai, E Lilly, and Pierre Farbre. TH reports grants or contracts, paid to their institution, from Bristol-Myers Squibb, Eisai, Exelixis, Johnson & Johnson, and Pfizer; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Astellas Pharma, Bristol-Myers Squibb, Eisai, Exelixis, Johnson & Johnson, and Pfizer; and participation on a data safety monitoring board or advisory board for Astellas Pharma, Bayer/Onyx, Bristol Myers Squibb, Exelixis, Johnson & Johnson, Novartis, and Pfizer. BMcG reports grants or contracts, paid to their institution from Exelixis, SeaGen, Pfizer, Bristol Myers Squibb and consulting fees from Astellas, Bristol-Myers Squibb, Calithera, Eisai, Exelixis, Pfizer, and SeaGen. TP reports research funding from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; consulting fees from Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; support for attending meetings or travel Astra Zeneca, Ipsen, MSD, Pfizer, and Roche. VG reports grants or contracts, paid to their institution, from AstraZeneca, Bristol-Myers Squibb, MSD, Pfizer, Ipsen; consulting fees from Bristol-Myers Squibb, Pfizer, Roche, MSD, Oncorena, PCI Biotech, Nanobiotix, Merck Serono, EUSA Pharm, Debiopharm, Eisai, and Apogepha; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Bristol Myers Squibb, Eisai, Ipsen, Janssen-Cilag, Merck Serono, MSD, Novartis, Pfizer, Roche, AstraZeneca, and Astellas; support for attending meetings or travel from Pfizer and Merck; participation on a data safety monitoring board or advisory board for Bristol-Myers Squibb, Ipsen, Eisai, PharmaMar, and PharmaMar; leadership or fiduciary role in other board, society, committee, or advocacy group from National Working Group AIO (Working Group on Internal Oncology in the German Cancer Society), German Cancer Society; and stock or stock options in AstraZeneca, Bristol-Myers Squibb, MSD, and SeaGen. BA reports grants or contracts from Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Ipsen, Janssen, Merck, MSD, Pfizer, and Roche; consulting fees from Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Ipsen, Janssen, Merck, MSD, Pfizer, and Roche; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events: Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Ipsen, Janssen, Merck, MSD, Pfizer, Roche; payment for expert testimony from Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Ipsen, Janssen, Merck, MSD, Pfizer, and Roche; and support for attending meetings or travel from Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Ipsen, Janssen, Merck, MSD, Pfizer, and Roche. SYR reports grants or contracts from Amgen, Merck, Bristol-Myers Squibb, MSD, Lilly, Daiichi Sankyo, Beigene, Eisai, and AstraZeneca; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Amgen, Lilly, Bristol-Myers Squibb, MSD, and Eisai; and participation on a data safety monitoring board or advisory board from Amgen, MSD, Bristol-Myers Squibb, Merck, Indivumed, Beigene, Eisai, and Daiichi Sankyo. AK reports payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Merck, Bristol-Myers Squibb, Ipsen, Eisai, Janssen, AbbVie; leadership or fiduciary role in for Kidney Cancer Canada; and stock in Verity Pharma. TAG reports grants or contracts from Pfizer, Roche, and Ipsen; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Ipsen, Lilly, Pfizer, Roche, Bristol-Myers Squibb, MSD, Eisai, Bayer, Janssen, Sanofi, and Astellas. JCG reports consulting fees for an advisory board meeting from Merck Sharp & Dohme (Australia), Bristol-Myers Squibb, and GlaxoSmithKline; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Janssen–Cilag, Ipsen, Merck Sharp and Dohme (Australia), and AstraZeneca (Australia); and support for attending meetings or travel AstraZeneca (Australia), GlaxoSmithKline, and MSD. MS reports grants or contracts from Pfizer, GlaxoSmithKline, AVEO, Bristol Myers Squibb, Novartis, Bayer, Roche/Genentech, Immatics, Wilex, Ipsen, Exelixis, and Eisai; consulting fees from Pfizer, GlaxoSmithKline, Novartis, Bayer, Roche, Aveo, EUSA Pharm, Astellas, Ipsen, Exelixis, Pelloton, Eisai, Bristol-Myers Squibb, MSD, Apogepha, and Oncorena; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Pfizer, GlaxoSmithKline, AVEO, Novartis, Bayer, EUSA Pharma, Astellas, Ipsen, Exelixis, Pelloton, Eisai, Bristol-Myers Squibb, MSD, and Apogepha; and support for attending meetings or travel from Pfizer, EUSAPharm, Ipsen, Eisai, Bristol-Myers Squibb, MSD, and Apogepha. JRM reports grants or contracts, paid to their institution from Corvus Pharmaceuticals, Eisai, Genentech/Roche, Lilly, Merck, Novartis, Peloton Therapeutics, Pfizer, Replimune, Seattle Genetics/Astellas, Sillajen, Tizona Therapeutics, Tocagen, and Vyriad, and consulting fees from Exelixis. RX, KM, and JMcK are employees of Eisai. RFP is an employee of and holds stock in Merck, Rahway, NJ, USA. CGP reports consulting fees from Angelini Pharma, AstraZeneca, Bristol-Myers Squibb, Eisai, Ipsen, and MSD; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Angelini Pharma, AstraZeneca, Bristol-Myers Squibb, Eisai, General Electric, Ipsen, and MSD; and participation on a data safety monitoring board or advisory board for Bristol-Myers Squibb, Eisai, MSD, the European Society of Medical Oncology, and the Italian Association for Medical Oncology. All other authors declare no competing interests. – Name: Comment Label: Comments Group: Commnt Data: Erratum in: Lancet Oncol. 2023 Apr;24(4):e146. doi: 10.1016/S1470-2045(23)00117-1.. (PMID: <searchLink fieldCode="PM" term="%2236990611%22">36990611)</searchLink> – Name: ChemicalData Label: Molecular Sequence Group: ChemData Data: ClinicalTrials.gov NCT02811861 – Name: NumberCAS Label: Substance Nomenclature Group: ID Data: 9HW64Q8G6G (Everolimus)<br />V99T50803M (Sunitinib)<br />EE083865G2 (lenvatinib)<br />0 (Phenylurea Compounds)<br />0 (Quinolines)<br />DPT0O3T46P (pembrolizumab)<br />0 (Antibodies, Monoclonal, Humanized) – Name: DateEntry Label: Entry Date(s) Group: Date Data: <i>Date Created: </i>20230301 <i>Date Completed: </i>20230307 <i>Latest Revision: </i>20260127 – Name: DateUpdate Label: Update Code Group: Date Data: 20260130 – Name: DOI Label: DOI Group: ID Data: 10.1016/S1470-2045(23)00049-9 – Name: AN Label: PMID Group: ID Data: 36858721 |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=cmedm&AN=36858721 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/S1470-2045(23)00049-9 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 228 Subjects: – SubjectFull: Female Type: general – SubjectFull: Humans Type: general – SubjectFull: Male Type: general – SubjectFull: Middle Aged Type: general – SubjectFull: Everolimus Type: general – SubjectFull: Follow-Up Studies Type: general – SubjectFull: Sunitinib Type: general – SubjectFull: Phenylurea Compounds Type: general – SubjectFull: Quinolines Type: general – SubjectFull: Antibodies, Monoclonal, Humanized Type: general – SubjectFull: Carcinoma, Renal Cell Type: general – SubjectFull: Kidney Neoplasms Type: general Titles: – TitleFull: Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Choueiri TK – PersonEntity: Name: NameFull: Eto M – PersonEntity: Name: NameFull: Motzer R – PersonEntity: Name: NameFull: De Giorgi U – PersonEntity: Name: NameFull: Buchler T – PersonEntity: Name: NameFull: Basappa NS – PersonEntity: Name: NameFull: Méndez-Vidal MJ – PersonEntity: Name: NameFull: Tjulandin S – PersonEntity: Name: NameFull: Hoon Park S – PersonEntity: Name: NameFull: Melichar B – PersonEntity: Name: NameFull: Hutson T – PersonEntity: Name: NameFull: Alemany C – PersonEntity: Name: NameFull: McGregor B – PersonEntity: Name: NameFull: Powles T – PersonEntity: Name: NameFull: Grünwald V – PersonEntity: Name: NameFull: Alekseev B – PersonEntity: Name: NameFull: Rha SY – PersonEntity: Name: NameFull: Kopyltsov E – PersonEntity: Name: NameFull: Kapoor A – PersonEntity: Name: NameFull: Alonso Gordoa T – PersonEntity: Name: NameFull: Goh JC – PersonEntity: Name: NameFull: Staehler M – PersonEntity: Name: NameFull: Merchan JR – PersonEntity: Name: NameFull: Xie R – PersonEntity: Name: NameFull: Perini RF – PersonEntity: Name: NameFull: Mody K – PersonEntity: Name: NameFull: McKenzie J – PersonEntity: Name: NameFull: Porta CG IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 03 Text: 2023 Mar Type: published Y: 2023 Identifiers: – Type: issn-electronic Value: 1474-5488 Numbering: – Type: volume Value: 24 – Type: issue Value: 3 Titles: – TitleFull: The Lancet. Oncology Type: main |
| ResultId | 1 |